a strong trendgold
Although spebrutinib did not demonstrate efficacy in RA, it displayed a strong trend towards improvement in RA clinical efficacy measures as well as a reduction in circulating bone resorption biomarkers, near complete BTK coverage, and a significant reduction in circulating transitional B cells and an increase in naive cells.